Overview

Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease

Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
This trial will assess the safety, efficacy and tolerability of ACZ885 in patients aged 4 years and younger with cryopyrin associated periodic syndromes (CAPS)
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals